Granules' Lamotrigine ANDA078982 Receives Approval Status
Granules has received an Approval Pending (AP) status for their ANDA078982 application for Lamotrigine.
Published: July 11, 2026
Updated: July 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Antiepileptic
Asset: Granules
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Granules
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The Approval Pending status for Granules' Lamotrigine indicates a significant shift in the competitive landscape for this generic product. Pharma strategy teams should assess the implications for pricing and market share as Granules prepares to enter the market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the final approval decision and market launch timelines for Lamotrigine from Granules.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.